Yomaris Pharma Private Limited
Founded in 2014 and headquartered in Maharashtra, India.
2014 | Thane, Maharashtra (India) | Active
Yomaris Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 10 Year, 5 Months
- Last Filing with ROC 31 Mar 2022
- Revenue Growth 13.34%
- Profit Growth 975.13%
- Ebitda 252.96%
- Net Worth 30.55%
- Total Assets 4.55%
About Yomaris Pharma
Yomaris Pharma Private Limited (YPPL) is a Private Limited Indian Non-Government Company incorporated in India on 10 September 2014 and has a history of Ten years and five months. Its registered office is in Thane, Maharashtra, India.
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2022. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rupesh Dundale and Harshad Dattaram serve as directors at the Company.
Company Details
- Location
Thane, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U51101MH2014PTC257952
- Company No.
257952
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
10 Sep 2014
- Date of AGM
30 Sep 2022
- Date of Balance Sheet
31 Mar 2022
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Healthcare
Who are the key members and board of directors at Yomaris Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rupesh Dundale  | Director | 10-Sep-2014 | Current |
| Harshad Dattaram | Director | 01-Sep-2015 | Current |
Financial Performance of Yomaris Pharma.
Yomaris Pharma Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 13.34% increase. The company also saw a substantial improvement in profitability, with a 975.13% increase in profit. The company's net worth Soared by an impressive increase of 30.55%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Yomaris Pharma?
Unlock access to Yomaris Pharma's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Yomaris Pharma?
Unlock and access historical data on people associated with Yomaris Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Yomaris Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Yomaris Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
